Ontunisertib

Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.

Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...